Eli Lilly and Company : Trading opportunity
Entry price | Target | Stop-loss | Potential |
---|
US$42.75 |
US$0 |
US$41.47 |
-100% |
---|
Eli Lilly one of the world's leading pharmaceutical groups, could regain its upward trend after having run out of steam.
The fundamentals support the stock with a gradual upward revision of earnings per share by analysts. Yet, the Thomson Reuters consensus expect sales to grow for the fiscal year at 22706 M USD against 24287 M USD for the previous year.
Technically, the uptrend in the medium and long term should protect the stock of a major downtrend. In the short term, a decline could lead the share to the USD 42 support. Therefore, a technical rebound will fix an objective near to the USD 44.50 short-term resistance.
Consequently, we expect a decline toward USD 42. The most active investors can buy the share in this area and target a return toward USD 44.50. A stop loss can be placed under the USD 41.5 support.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.